Photodynamic diagnosis (PDD) by using Talaporfin and Sie-P2 against local failure after chemoradiotherapy or radiotherapy for esophageal cancer

Phase 1

• Conditions: esophageal cancer

• Registration Number: JPRN-UMIN000029734
• Lead Sponsor: agoya City University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-10-27
• Study Completion: 2018-12-04
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 2

Inclusion Criteria

Not provided

Exclusion Criteria

1. the patinet who can not be inserted endoscope 2. with malignant hypertension, conjestive heart failure, liver dysfunction, myocardil infarction within 3 months, endostage of liver cirrhosis, poor controled DM, severe lung fibrosis, active pneumonitis 3. with active infection 4. inability to comply the sun shade restrictions 5. porphyria 6. severe psychosomatic disturbance 7. allergy against Talaporfin 8. for women, pregnancy or lactation, or unwillingness to use contraception 9. T3 or T4 10. larger than 3cm in diameter 11. half the circumference of the lumen or less 12. invasion to the cervical esophagus 13. patients who judged by the investigator that enrollment was inappropriate

Study & Design

• Study Type: Interventional
• Study Design: Not specified